Cell-Based Assay Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||390837|
|出版日期||內容資訊||英文 120 Pages
|細胞化驗的全球市場:各產品、技術、應用、終端用戶、地區成長率，趨勢及預測(2018年∼2023年) Cell-Based Assay Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年02月01日||內容資訊: 英文 120 Pages||
The cell-based assay market will show rapid growth due to the rising prevalence of chronic diseases and lifestyle disorders, increasing investments in R&D for drug discovery and the rise in technological advancements in cell-based methodologies.
The rising prevalence of chronic diseases and lifestyle disorders, such as cancer, cardiovascular, diabetes, and neurological disorders is one of the primary factors fueling the market growth. According to the WHO, chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. It has been calculated that, in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. The proportion of the burden of NCDs is expected to increase to 57% by 2020.
Almost half of the total chronic disease deaths are attributable to cardiovascular diseases, obesity and diabetes are also showing increasing trends. Thus, the rise in chronic diseases leads to demand growth for cell-based assays for new drug discoveries, making it a vital factor for market growth. In addition, the demand for cell-based assay has increased significantly owing to a surge in cell-based applications in drug discovery and the rise in technological advancements in cell-based assays methodologies.
Drug Discovery is Expected to be the Largest Growing Segment Under Application in the Cell-Based Assay Market
The drug discovery segment is anticipated to show high growth in the market and this growth can be attributed to the increase in the R&D investment by biopharmaceutical companies. In addition, the rise in the prevalence of chronic diseases, such as cancer, osteoarthritis, cardiovascular diseases, and diabetes, is fueling the demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market. In cell-based assays, functional cells are used as diagnostic tools in research for new drugs that help in drug discovery.
North America is Found Leading the Cell-Based Assay Market
North America is the leading region across the world in terms of market share owing to the well-established healthcare sector along with the high adoption of cell-based therapies. In the United States, the prevalence of chronic diseases, such as cancer, osteoarthritis, and diabetes, is increasing that is fueling the demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market.
Asia Pacific is expected to register the highest CAGR in the market during the forecast period. Growth in the APAC region is largely driven by the increasing R&D investment by the government and increasing infrastructural development in the region.
The key players operating in the global cell-based assay market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., and Promega Corporation. Product innovation and ongoing R&D activities to develop advanced technologies have helped in boosting the growth of the market.